Tiziana Life Sciences Ltd TLSA
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Tiziana Life Sciences Ltd (TLSA) is a healthcare company listed in the US with a market value of about $73M.
Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is financial health (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -140%.
About Tiziana Life Sciences
Tiziana Life Sciences is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. It was profitable in 0 of the last 9 years in our data.
Score: 0.2 / 5
Checks passed
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — |
| Net income | -$12M | -$18M | -$15M | -$23M | -$26M | -$9M | -$8M | -$9M | -$10M |
| Free cash flow | -$2M | — | — | -$22M | -$11M | -$7M | — | -$8M | — |
| EPS (diluted) | $-0.09 | $-0.14 | $-0.12 | $-0.18 | $-0.21 | $-0.07 | $-0.06 | $-0.07 | $-0.08 |
| Net margin | — | — | — | — | — | — | — | — | — |
| ROIC | -284.3% | -256.6% | -58.9% | -58.2% | -41.2% | -11.1% | -10.4% | — | -223.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $7.86, 1280% above the current price; targets range from $6.88 to $8.85; the consensus rating is “Strong buy”; expected EPS is $-0.13 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Tiziana Life Sciences pay a dividend?
Not currently.
Is Tiziana Life Sciences a good stock to buy?
We do not give buy or sell advice. Tiziana Life Sciences scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.